FBXW7 and cancer: Consistent with the reported resistance of FBXW7‐mutant human cancer cells to paclitaxel (Inuzuka et al, 2011; Wertz et al, 2011), oxaliplatin (Fang et al, 2015; Li et al, 2015), 5‐fluorouracil (5‐FU; Lorenzi et al, 2016; Li et al, 2019) and doxorubicin (Li et al, 2016), Fbxw7−/− mES cells became significantly enriched after 48 h of culture in the presence of these drugs (Appendix Fig S2B).